Selecta Biosciences Inc. (Nasdaq: SELB) presented positive new data from on ongoing Phase 2 trial of SEL-212 to treat chronic severe gout but the stock price plunged $1.68 to close at $9.36.
Selecta Biosciences drops despite positive data
April 10, 2018 at 17:43 PM EDT
